title: [Administration of low-dose albumin-bound paclitaxel for the treatment of advanced and recurrent breast cancer patients].
abstract: A recent foreign clinical trial showed albumin-bound paclitaxel(260mg/m2 tri-weekly)to have a better response for metastatic breast cancer(MBC)than did treatment with paclitaxel alone(175mg/m2 tri-weekly). It was sometimes difficult to control the occurrence of side effects, such as neutropenia and neuropathy, especially after many treatments. The effect of low-dose albumin-bound paclitaxel(180-220mg/m2 tri-weekly)was evaluated in 8 patients with MBC. The overall response rate was 62. 5%(CR 1, PR 4), and 2 cases had Grade 3/4 toxicity(Grade 3 neutropenia); however, all patients were manageable. In addition, there was a good response rate(50%, PR 3)among the patients previously treated with paclitaxel. Because patient's "care" is as important as the "cure" in the treatment of MBC, an effective and well-tolerated regimen is recommended for patients with this disease. Low-dose albumin-bound paclitaxel was effective with reduced side effects, even after PTX treatment. Therefore, albumin-bound paclitaxel may be an optional treatment for MBC after any treatment.
authors.affiliation: Dept. of Surgery, Nishisaitama-Chuo National Hospital.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kawamura
authors.forename: Satoko
authors.initials: S
authors.lastname: Nakano
authors.forename: Shigeya
authors.initials: S
authors.lastname: Kyoda
authors.forename: Isao
authors.initials: I
authors.lastname: Tabei
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yoshida
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Takeyama
mesh_terms: D000368:Aged; D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D014057:Tomography, X-Ray Computed
chemical_list: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel